Results 151 to 160 of about 2,473 (178)

Onychomycosis Treated with Itraconazole or Griseofulvin Alone with and without a Topical Antimycotic or Keratolytic Agent

International Journal of Dermatology, 1991
Abstract: An open, comparative, randomized study was conducted using griseofulvin or itraconazole for the treatment of onychomycosis of the foot. Group I (45 patients) received itraconazole and Group II (45 patients) received griseofulvin. Each group was divided into three subgroups that received different topical treatment: antimycotic cream ...
R, Arenas, G, Fernández, L, Domínguez
openaire   +3 more sources

Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5.

Journal of Clinical Oncology, 2010
9017 Background: HFS is a dose-limiting toxicity of capecitabine, occurring in 43-71% of patients. No effective preventative treatment has been definitively demonstrated.
S. L. Wolf, R. Qin, S. P. Menon, K. M. Rowland, J. W. Kugler, P. J. Flynn, D. Christian, D. Satele, J. L. Berenberg, C. L. Loprinzi   +9 more
openaire   +2 more sources

Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in combination with topical keratolytic agents

Yearbook of Dermatology and Dermatologic Surgery, 2011
George M. Martin
openaire   +2 more sources

[Salicylic acid as a keratolytic agent].

Annales de dermatologie et de venereologie, 2002
J.-C. Béani
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Molecular imaging in oncology: Current impact and future directions

Ca-A Cancer Journal for Clinicians, 2022
Steven P Rowe, Martin G Pomper
exaly  

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly  

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Recent progress in the treatment of cancer in children

Ca-A Cancer Journal for Clinicians, 2021
Theodore W Laetsch
exaly  

Improving the outcome for children with cancer: Development of targeted new agents

Ca-A Cancer Journal for Clinicians, 2015
Peter C Adamson
exaly